Peter Marks, CBER (MDA USA via Twitter)
June 11, 2020 06:39 AM EDTUpdated 06:51 AM
FDA+
Coronavirus

Pe­ter Marks dish­es on Covid-19 vac­cine de­vel­op­ment at BIO

Michael Mezher

Pe­ter Marks, di­rec­tor of the FDA’s Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) told a pan­el at BIO Dig­i­tal he thinks glob­al reg­u­la­tors will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times